CClinicalTrials.gg
Active, not recruitingNCT04700111ASHUpdated May 5, 2026

Lag of Accommodation With DOT Spectacle Lenses

An interventional study of DOT Pattern and Control Spectacles in Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in Contrast, sponsored by SightGlass Vision, Inc.. Active, not recruiting at 1 site in Canada. Open to participants aged 6 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by SightGlass Vision, Inc. · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
6 Years to 18 Years
Sex
All
01

Study summary

The objective of the study is to measure the difference in the lag of accommodation between DOT spectacle lenses and control spectacles.

02

Conditions studied

  • Myopia, Myopia Progression, Lag of Accommodation, Hyperopic Retinal Blur, Reduction in Contrast

Browse trials for

03

In context

Myopia

984 studies on the registry are indexed under Myopia; 210 are open to participants now.

This study's enrollment of 30 is below the median of 80 across 783 interventional studies indexed under Myopia.

Browse Myopia studies →

Lead sponsor

SightGlass Vision, Inc. is the lead sponsor of 14 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

A person is eligible for inclusion in the study if he/she:

  1. Age 6-18 years of age, with a maximum of 6 of the first 25 completed participants being older than 14 years of age.
  2. Is able to read (or be read to), understand and sign the assent document if under 17 years old or is able to read, understand and sign the consent document if aged 17 or 18 years.
  3. Is under 17 years old and is accompanied by a parent or legal guardian who is able to read, understand and sign the parental information and permission document.
  4. Should be emmetropic by non-cycloplegic auto-refraction, which means both refractive meridians should be within +1.00D and -1.00D.
  5. Is willing and able to follow instructions.

A person will be excluded from the study if he/she:

  1. Is participating in any concurrent clinical or research study.
  2. Have a history of myopia control treatment in the past year.
  3. Has amblyopia in either eye or known to have any other binocular vision disorder, such as accommodative insufficiency.
  4. Has any known active ocular disease and/or infection.
  5. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable. Examples include diabetes mellitus, hyperthyroidism.
  6. Is using any systemic or topical medications that in the opinion of the investigator may affect a study outcome variable. Examples include Atropine eye drops.
  7. Has undergone strabismus surgery, refractive error surgery or intraocular surgery.
  8. Is a child of a member of the study team.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Treatment 1 - DOT Pattern

    Spectacle lens or treatment 1

    Device: DOT Pattern

  • Active comparator
    Treatment 2 - Control Spectacles

    Comparator lens or control arm

    Device: Control Spectacles

Interventions

  • DeviceDOT Pattern

    DOT Pattern Spectacle Lens

  • DeviceControl Spectacles

    Control lens

06

What researchers measure

Primary outcomes

  1. Best vision sphere

    1\) Autorefractor spherical equivalent refraction measured at distance and at 40cm with each pair of treatment spectacles

    Time frame: 90 minutes

07

Study locations

1 site
  • Centre for Ocular Research and Education
    Waterloo, Ontario N2L 3G1, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04700111
Lead sponsor
SightGlass Vision, Inc.
Collaborators
University of Waterloo
Responsible party
Sponsor
First posted
Jan 7, 2021
Start date
Feb 1, 2022
Primary completion
Jun 9, 2022
Completion
Dec 31, 2026 (estimated)
Last update
May 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion